If your employer covers a weight-loss drug today, the document that tells you whether that continues next year is the summary of benefits and coverage you will get during open enrollment. For a meaningful minority of workers, it will read differently than last year's.
Two benefits surveys point the same direction. A Business Group on Health survey of 105 large employer members, fielded in February and March 2026, found that 67 percent currently cover GLP-1 medications for weight management. Of those, only 72 percent said they were likely to maintain that coverage in 2027, meaning roughly one in ten expects to drop it.
Separately, benefits consultancy Mercer reported that among employers with 500 or more workers, 6 percent dropped coverage in 2026 and 5 percent plan to drop or are considering dropping for 2027. Mercer put current coverage among that group at 44 percent for obesity.
These are surveys of employers who chose to respond, not a census. They describe direction and rough magnitude, not a measured national coverage rate, and the two surveys disagree on the baseline because they define large employers differently and drew different samples.
The Numbers Behind the Trend, and What Each One Measures
The cost pressure driving this is not what most people assume. Per-unit prices have come down. Utilization has gone up faster.
Oral GLP-1s arrived this year, with Novo Nordisk's Wegovy pill launching in January and Eli Lilly's Foundayo in April, and they pulled in people who had never tried an injectable. Eighty-seven percent of employers surveyed by Business Group on Health said they expect oral availability to increase overall demand. Louis Zollo, a pharmacy practice leader at the consultancy Segal, told Reuters that even with unit costs falling, "the patient population keeps growing."
Ellen Kelsay, president and chief executive of Business Group on Health, said the survey reflects "the tremendous concern employers have regarding these medications" from a cost and financial viability standpoint.
A separate measure tracks what this looks like from the patient side. GoodRx research tracking commercial coverage found that as of July 2026, the number of people with no commercial coverage for Zepbound had risen 18 percent compared with 2025, leaving more than 114 million people without coverage for that drug. Among those who do have coverage for a GIP or GLP-1 agonist prescribed for weight loss, 88 percent still face additional requirements such as prior authorization.
Coverage also moves in both directions. CVS Caremark removed Zepbound from its standard commercial formulary in mid-2025 and has said it will add the drug back as an additional preferred option effective October 1, 2026. Employers whose plans follow that formulary may see access widen even as others narrow.
Reading a Summary of Benefits for the Exclusion
Employer coverage decisions rarely announce themselves. They appear as language in plan documents, and knowing where to look shortens the search considerably.
Start with the prescription drug section of the summary of benefits and coverage, then request the full formulary, which is a separate and longer document. Search both for the terms "weight loss," "weight management," "anti-obesity," and the specific brand names Wegovy, Zepbound, and Foundayo.
The distinction that matters most is indication. Many plans exclude GLP-1s prescribed for weight loss while continuing to cover the same molecules prescribed for type 2 diabetes. A plan that covers Ozempic and Mounjaro but excludes Wegovy and Zepbound is drawing that line, not dropping the drug class.
Look also for a specialty pharmacy requirement, which routes the prescription through a designated pharmacy rather than a local one, and for quantity limits, which cap how much can be dispensed at once. Neither is an exclusion, but both change how a prescription gets filled.
Some employers grandfather people already on treatment. Those provisions typically appear as an effective date paired with a higher copay tier, and they are worth finding before the plan year turns because the enrollment window is when they are documented.
Prior Authorization and Step Therapy in Plain Language
The two most common conditions on continued coverage sound technical and are not.
Prior authorization means the plan will not pay until it approves the specific prescription in advance. For weight-loss drugs, the criteria typically involve a documented body mass index threshold, sometimes a related condition such as hypertension or sleep apnea, and often documentation of prior attempts at weight management. Approvals are usually time-limited and require renewal.
Step therapy requires trying a less expensive option first and documenting that it failed or was not tolerated. In this category, it can mean an older medication, a different GLP-1, or a structured lifestyle program.
Employers keeping coverage are leaning on both, along with mandatory participation in a weight management program, verification of clinical eligibility through biometric data, and restricting which prescribers can write for the drug. Those are the conditions Business Group on Health identified among employers continuing to cover.
Understanding the difference matters because the responses differ. A prior authorization denial can be appealed with clinical documentation. A plan exclusion cannot be appealed on medical grounds, because the plan does not cover the benefit at all.
Questions Worth Asking Before the Plan Year Closes
A benefits administrator can answer most of this in one email, and asking before enrollment closes is far easier than discovering it at a pharmacy counter in January.
Ask directly whether GLP-1 medications for weight management are covered in the new plan year, and whether that differs from coverage for diabetes. Ask whether prior authorization or step therapy applies, what the specific criteria are, and whether people currently on treatment are grandfathered. Ask which pharmacy must fill it and what the copay or coinsurance tier is.
If a spouse has employer coverage, compare both plans during enrollment rather than defaulting to the current one. Coverage for this drug class can differ substantially between two employers in the same city.
For anyone losing coverage, several routes exist. Manufacturer direct-to-consumer channels now sell oral options at lower monthly prices than list, and both major manufacturers operate patient assistance programs with income eligibility criteria. A prescriber may be able to document a diabetes or other covered indication where one genuinely applies, though that determination belongs to the clinician and the diagnosis must be real. Nobody should stop a GLP-1 abruptly because of a coverage change without talking to a prescriber, since weight regain after discontinuation is well documented.
What happens next is the enrollment calendar. Most large employers finalize 2027 plan designs in late summer and communicate them in October and November. Novo Nordisk has said it will move to a unified list price of $675 across Ozempic, Wegovy, and Rybelsus beginning January 1, 2027, which could shift employer math again. MedicalDaily will report significant formulary and coverage changes as they are announced.
Frequently Asked Questions
Are employers dropping weight-loss drug coverage? Some are. Among large employers currently covering GLP-1s for weight management, roughly one in ten told Business Group on Health it does not expect to continue in 2027.
Is that a national coverage rate? No. These are voluntary employer surveys describing direction and rough magnitude. Two surveys disagree on the baseline because they define large employers differently.
Why is coverage tightening if drug prices fell? Per-unit costs came down, but utilization rose faster, partly because new oral options attracted people who had not tried injectables.
Where do I check my own coverage? The prescription drug section of your summary of benefits and coverage, plus the full formulary. Search for "weight loss," "anti-obesity," and the brand names.
What is the difference between prior authorization and step therapy? Prior authorization requires plan approval before it pays. Step therapy requires trying a less expensive option first and documenting that it failed or was not tolerated.
Can I appeal a denial? A prior authorization denial can be appealed with clinical documentation. A plan exclusion generally cannot be appealed on medical grounds because the benefit is not covered.
What if I lose coverage mid-treatment? Talk to your prescriber before stopping. Manufacturer direct channels and patient assistance programs are options, and weight regain after discontinuation is well documented.
